Verastem Inc

Verastem, Inc. is a development-stage biopharmaceutical company focused on developing and commercializing drugs for cancer treatment in the United States. Its product candidates include Avutometinib, an orally administered small molecule dual RAF/MEK inhibitor designed to block MEK kinase activity and compensatory MEK reactivation by upstream RAF, targeting the RAS/MAPK signaling pathway commonly activated in various cancers, and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is conducting clinical studies such as RAMP 301, a randomized global confirmatory trial of Avutometinib and Defactinib in recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open-label trial; FRAME, an investigation in KRAS mutant cancers; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for Avutometinib-containing products and with Pfizer Inc. for FAK inhibitors, a clinical collaboration with Amgen, Inc. on the combination of Avutometinib with LUMAKRAS, and a discovery and development collaboration with GenFleet Therapeutics for RAS pathway-driven cancers. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.